Literature DB >> 26068307

The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities.

Elizabeth Stewart1, Sara Federico1, Asa Karlstrom2, Anang Shelat3, Andras Sablauer4, Alberto Pappo1, Michael A Dyer5.   

Abstract

Significant advances have been made over the past 25 years in our understanding of the most common adult solid tumors such as breast, colon, lung and prostate cancer. Much less is known about childhood solid tumors because they are rare and because they originate in developing organs during fetal development, childhood and adolescence. It can be very difficult to study the cellular origins of pediatric solid tumors in developing organs characterized by rapid proliferative expansion, growth factor signaling, developmental angiogenesis, programmed cell death, tissue reorganization and cell migration. Not only has the etiology of pediatric cancer remained elusive because of their developmental origins, but it also makes it more difficult to treat. Molecular targeted therapeutics that alter developmental pathway signaling may have devastating effects on normal organ development. Therefore, basic research focused on the mechanisms of development provides an essential foundation for pediatric solid tumor translational research. In this article, we describe new resources available for the developmental biology and oncology research communities. In a companion paper, we present the detailed characterization of an orthotopic xenograft of a pediatric solid tumor derived from sympathoadrenal lineage during development.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Childhood solid tumors; Epigenomics; Genetically engineered mouse models; Genomics; Xenograft

Mesh:

Year:  2015        PMID: 26068307      PMCID: PMC4600003          DOI: 10.1016/j.ydbio.2015.03.001

Source DB:  PubMed          Journal:  Dev Biol        ISSN: 0012-1606            Impact factor:   3.582


  60 in total

Review 1.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

Review 2.  Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.

Authors:  R B Raney; J R Anderson; F G Barr; S S Donaldson; A S Pappo; S J Qualman; E S Wiener; H M Maurer; W M Crist
Journal:  J Pediatr Hematol Oncol       Date:  2001-05       Impact factor: 1.289

3.  Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.

Authors:  Shizhen Zhu; Jeong-Soo Lee; Feng Guo; Jimann Shin; Antonio R Perez-Atayde; Jeffery L Kutok; Scott J Rodig; Donna S Neuberg; Daniel Helman; Hui Feng; Rodney A Stewart; Wenchao Wang; Rani E George; John P Kanki; A Thomas Look
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

4.  PHOX2B genotype allows for prediction of tumor risk in congenital central hypoventilation syndrome.

Authors:  Delphine Trochet; Louise M O'Brien; David Gozal; Ha Trang; Agneta Nordenskjöld; Béatrice Laudier; Pär-Johan Svensson; Sabine Uhrig; Trevor Cole; Stephan Niemann; Arnold Munnich; Claude Gaultier; Stanislas Lyonnet; Jeanne Amiel
Journal:  Am J Hum Genet       Date:  2005-01-18       Impact factor: 11.025

5.  Risk factors for childhood melanoma in Queensland, Australia.

Authors:  D C Whiteman; P Valery; W McWhirter; A C Green
Journal:  Int J Cancer       Date:  1997-01-06       Impact factor: 7.396

6.  Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005.

Authors:  Simona Ognjanovic; Amy M Linabery; Bridget Charbonneau; Julie A Ross
Journal:  Cancer       Date:  2009-09-15       Impact factor: 6.860

7.  Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project.

Authors:  Yaël P Mossé; Rebecca J Deyell; Frank Berthold; Akira Nagakawara; Peter F Ambros; Tom Monclair; Susan L Cohn; Andrew D Pearson; Wendy B London; Katherine K Matthay
Journal:  Pediatr Blood Cancer       Date:  2013-09-13       Impact factor: 3.167

8.  Prevalence and functional consequence of PHOX2B mutations in neuroblastoma.

Authors:  E H Raabe; M Laudenslager; C Winter; N Wasserman; K Cole; M LaQuaglia; D J Maris; Y P Mosse; J M Maris
Journal:  Oncogene       Date:  2007-07-16       Impact factor: 9.867

9.  Targeting oxidative stress in embryonal rhabdomyosarcoma.

Authors:  Xiang Chen; Elizabeth Stewart; Anang A Shelat; Chunxu Qu; Armita Bahrami; Mark Hatley; Gang Wu; Cori Bradley; Justina McEvoy; Alberto Pappo; Sheri Spunt; Marcus B Valentine; Virginia Valentine; Fred Krafcik; Walter H Lang; Monika Wierdl; Lyudmila Tsurkan; Viktor Tolleman; Sara M Federico; Chris Morton; Charles Lu; Li Ding; John Easton; Michael Rusch; Panduka Nagahawatte; Jianmin Wang; Matthew Parker; Lei Wei; Erin Hedlund; David Finkelstein; Michael Edmonson; Sheila Shurtleff; Kristy Boggs; Heather Mulder; Donald Yergeau; Steve Skapek; Douglas S Hawkins; Nilsa Ramirez; Philip M Potter; John A Sandoval; Andrew M Davidoff; Elaine R Mardis; Richard K Wilson; Jinghui Zhang; James R Downing; Michael A Dyer
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

10.  The genomic landscape of childhood and adolescent melanoma.

Authors:  Charles Lu; Jinghui Zhang; Panduka Nagahawatte; John Easton; Seungjae Lee; Zhifa Liu; Li Ding; Matthew A Wyczalkowski; Marcus Valentine; Fariba Navid; Heather Mulder; Ruth G Tatevossian; James Dalton; James Davenport; Zhirong Yin; Michael Edmonson; Michael Rusch; Gang Wu; Yongjin Li; Matthew Parker; Erin Hedlund; Sheila Shurtleff; Susana Raimondi; Vadodaria Bhavin; Yergeau Donald; Elaine R Mardis; Richard K Wilson; William E Evans; David W Ellison; Stanley Pounds; Michael Dyer; James R Downing; Alberto Pappo; Armita Bahrami
Journal:  J Invest Dermatol       Date:  2014-09-30       Impact factor: 8.551

View more
  36 in total

Review 1.  Challenges and Opportunities for Childhood Cancer Drug Development.

Authors:  Peter J Houghton; Raushan T Kurmasheva
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

Review 2.  Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group.

Authors:  Ryan D Roberts; Michael M Lizardo; Damon R Reed; Pooja Hingorani; Jason Glover; Wendy Allen-Rhoades; Timothy Fan; Chand Khanna; E Alejandro Sweet-Cordero; Thomas Cash; Michael W Bishop; Meenakshi Hegde; Aparna R Sertil; Christian Koelsche; Lisa Mirabello; David Malkin; Poul H Sorensen; Paul S Meltzer; Katherine A Janeway; Richard Gorlick; Brian D Crompton
Journal:  Cancer       Date:  2019-07-29       Impact factor: 6.860

3.  PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.

Authors:  Berkley E Gryder; Marielle E Yohe; Hsien-Chao Chou; Xiaohu Zhang; Joana Marques; Marco Wachtel; Beat Schaefer; Nirmalya Sen; Young Song; Alberto Gualtieri; Silvia Pomella; Rossella Rota; Abigail Cleveland; Xinyu Wen; Sivasish Sindiri; Jun S Wei; Frederic G Barr; Sudipto Das; Thorkell Andresson; Rajarshi Guha; Madhu Lal-Nag; Marc Ferrer; Jack F Shern; Keji Zhao; Craig J Thomas; Javed Khan
Journal:  Cancer Discov       Date:  2017-04-26       Impact factor: 39.397

4.  Biallelic Dicer1 Loss Mediated by aP2-Cre Drives Angiosarcoma.

Authors:  Jason A Hanna; Catherine J Drummond; Matthew R Garcia; Jonathan C Go; David Finkelstein; Jerold E Rehg; Mark E Hatley
Journal:  Cancer Res       Date:  2017-09-15       Impact factor: 12.701

5.  HNRNPH1 is required for rhabdomyosarcoma cell growth and survival.

Authors:  Yanfeng Li; Jesse Bakke; David Finkelstein; Hu Zeng; Jing Wu; Taosheng Chen
Journal:  Oncogenesis       Date:  2018-01-24       Impact factor: 7.485

6.  Positron Emission Tomography Detects In Vivo Expression of Disialoganglioside GD2 in Mouse Models of Primary and Metastatic Osteosarcoma.

Authors:  Elizabeth R Butch; Paul E Mead; Victor Amador Diaz; Heather Tillman; Elizabeth Stewart; Jitendra K Mishra; Jieun Kim; Armita Bahrami; Jason L J Dearling; Alan B Packard; Shana V Stoddard; Amy L Vāvere; Yuanyuan Han; Barry L Shulkin; Scott E Snyder
Journal:  Cancer Res       Date:  2019-04-23       Impact factor: 12.701

7.  Activation of Estrogen Receptor Alpha by Decitabine Inhibits Osteosarcoma Growth and Metastasis.

Authors:  Maria Angeles Lillo Osuna; Jesus Garcia-Lopez; Ikbale El Ayachi; Iram Fatima; Aysha B Khalid; Jerusha Kumpati; Alexandria V Slayden; Tiffany N Seagroves; Gustavo A Miranda-Carboni; Susan A Krum
Journal:  Cancer Res       Date:  2018-12-28       Impact factor: 12.701

Review 8.  Osteosarcoma in the Post Genome Era: Preclinical Models and Approaches to Identify Tractable Therapeutic Targets.

Authors:  Wilson Castillo-Tandazo; Anthony J Mutsaers; Carl R Walkley
Journal:  Curr Osteoporos Rep       Date:  2019-10       Impact factor: 5.096

Review 9.  Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments.

Authors:  P Zarzosa; N Navarro; I Giralt; C Molist; A Almazán-Moga; I Vidal; A Soriano; M F Segura; R Hladun; A Villanueva; S Gallego; J Roma
Journal:  Clin Transl Oncol       Date:  2016-10-07       Impact factor: 3.405

10.  Nucleome Dynamics during Retinal Development.

Authors:  Jackie L Norrie; Marybeth S Lupo; Beisi Xu; Issam Al Diri; Marc Valentine; Daniel Putnam; Lyra Griffiths; Jiakun Zhang; Dianna Johnson; John Easton; Ying Shao; Victoria Honnell; Sharon Frase; Shondra Miller; Valerie Stewart; Xin Zhou; Xiang Chen; Michael A Dyer
Journal:  Neuron       Date:  2019-09-04       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.